Payment overview · 2025
General Payments
$549.30
30 reported records · 10 companies
Healthcare provider profile · identity verified
Kevin D Sweet, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1629073846
Verified facts
What the public records show
CMS Open Payments records show Kevin D Sweet, MD received $549.30 in general payments during 2025 across 30 reported records.
Lilly USA, LLC accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.24 | 24.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $108.80 | 19.8% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.49 | 14.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.43 | 9.5% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.19 | 8.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.18 | 6.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.66 | 5.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.67 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.82 | 3.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.82 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.30 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.77 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.77 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.43 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.43 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.50 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.29 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.30 | 3 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $47.19 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 272 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 172 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 574 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 122 |
| Omeprazole | Omeprazole | 478 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 131 |
| Lisinopril | Lisinopril | 398 | 102 |
| Gabapentin | Gabapentin | 342 | 68 |
| Losartan Potassium | Losartan Potassium | 337 | 89 |
| Potassium Chloride | Potassium Chloride | 332 | 95 |
| Furosemide | Furosemide | 302 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 72 |
| Eliquis | Apixaban | 272 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 66 |
| Meloxicam | Meloxicam | 219 | 51 |
| Metformin Hcl Er | Metformin Hcl | 217 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 46 |
| Simvastatin | Simvastatin | 175 | 49 |
| Tramadol Hcl | Tramadol Hcl | 174 | 37 |
| Metformin Hcl | Metformin Hcl | 169 | 47 |
| Alendronate Sodium | Alendronate Sodium | 167 | 49 |
| Alprazolam | Alprazolam | 166 | 28 |
| Ozempic | Semaglutide | 164 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 43 |
| Sertraline Hcl | Sertraline Hcl | 156 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 27 |
| Allopurinol | Allopurinol | 148 | 42 |
| Trazodone Hcl | Trazodone Hcl | 141 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 38 |
| Glimepiride | Glimepiride | 136 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 39 |
| Farxiga | Dapagliflozin Propanediol | 114 | 26 |
| Spironolactone | Spironolactone | 114 | 39 |
| Carvedilol | Carvedilol | 112 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 43 |
| Benazepril Hcl | Benazepril Hcl | 108 | 29 |
| Famotidine | Famotidine | 108 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 33 |
| Ezetimibe | Ezetimibe | 100 | 29 |
| Montelukast Sodium | Montelukast Sodium | 100 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 28 |
| Lorazepam | Lorazepam | 97 | 18 |
| Valsartan | Valsartan | 93 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 91 | 19 |
| Clonazepam | Clonazepam | 89 | 14 |
| Donepezil Hcl | Donepezil Hcl | 86 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 36 |
| Cephalexin | Cephalexin | 83 | 33 |
| Trulicity | Dulaglutide | 76 | 18 |
| Celecoxib | Celecoxib | 73 | 17 |
| Chlorthalidone | Chlorthalidone | 73 | 17 |
| Prednisone | Prednisone | 73 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 13 |
| Xarelto | Rivaroxaban | 67 | 16 |
| Temazepam | Temazepam | 66 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 66 | 19 |
| Bupropion Xl | Bupropion Hcl | 64 | 16 |
| Finasteride | Finasteride | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Jardiance | Empagliflozin | 56 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 15 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 16 |
| Ibuprofen | Ibuprofen | 48 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 13 |
| Telmisartan | Telmisartan | 43 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 13 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 35 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Linzess | Linaclotide | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 15 |
| Cefdinir | Cefdinir | 27 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 17 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate In Water | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 11 |
| Torsemide | Torsemide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.30 · 30 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, COMIRNATY, ELIQUIS, GIVLAARI, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error